Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||DT01 + Radiotherapy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DT01||DT01 consists of nanoparticles containing short interfering DNA that mimics DNA double strand breaks that are linked to cholesterol, resulting in activation of the DNA damage response in the liver, and potentially leading to increased sensitivity to chemotherapeutic agents (PMID: 26637369, PMID: 28374075, PMID: 27140316).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||DT01 + Radiotherapy||Phase I||Actionable||In a Phase I trial, DT01 treatment enhanced the sensitivity of radiotherapy, resulting in an objective response in 59% (45/76) of lesions from 21 melanoma patients, including 23 complete responses (PMID: 27140316; NCT01469455).||27140316|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|